Why are these ASX 200 healthcare shares sinking today?

ASX 200 healthcare shares were among some of the top performers in the race to the COVID vaccine. Why are they slipping now?
The post Why are these ASX 200 healthcare shares sinking today? appeared first on The Motley Fool Australia. –

falling healthcare asx share price Mesoblast capital raising

As the world raced for vaccines and medicines in 2020 to prevent and treat the COVID-19 pandemic, S&P/ASX 200 Index (ASX: XJO) healthcare shares had some periods of strong outperformance.

But in recent weeks that outperformance, for most, has evaporated.

ResMed and CSL share prices sliding

The ResMed Inc (ASX: RMD) share price has fallen 1.6% in intraday trading and is down by around 11% year to date. ResMed is best known for its respiratory medical devices.

Meanwhile, the CSL Limited (ASX: CSL) share price is down a significant 4.63% at the time of writing. This ASX 200 healthcare heavyweight has a historic focus on influenza vaccine development. And in 2021, CSL shares have fallen by around 10%.

By comparison, the ASX 200 is down 0.5% in intraday trading and up 1% year to date.

So what’s going on?

Why are ASX 200 healthcare shares under pressure?

It’s not just ASX 200 healthcare shares that have come under pressure in recent weeks.

The phenomenon is happening in share markets around the world. And it’s closely linked with the rollout of the coronavirus vaccine.

As Bloomberg reports:

Equity investors are steering clear of drug makers and health-care service providers as continued progress in distributing COVID-19 vaccines adds to the momentum in stocks poised to benefit most from an economic reopening.

According to the article, five out of six of the largest healthcare shares listed on the S&P 500 Index (SP: .INX) had lost ground in afternoon trading yesterday (overnight Aussie time).

ABIOMED Inc. (NASDAQ: ABMD) closed the day down 5.4% and has slipped another 1% in after hours trading.

DexCom Inc. (NASDAQ: DXCM), with a market capitalisation of US$35.5 billion, lost 5.9% by the closing bell.

Commenting on the healthcare sector’s performance, Goldman Sachs strategist Asad Haider said, “Investor conversations point to a generalist buyer’s strike across the sector that likely needs some catalyst to reverse course.”

I’m not sure what type of catalyst Haider is referring to. But let’s hope it’s not the unexpected need for even more respiratory devices and vaccines.

In the meantime, the declining share prices of both CSL and ResMed haven’t prevented several leading brokers from giving these ASX 200 blue chip shares buy and outperform ratings.

Where to invest $1,000 right now

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

See The 5 Stocks

*Returns as of February 15th 2021

More reading

Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and recommends Abiomed and DexCom. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has recommended DexCom and ResMed Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Why are these ASX 200 healthcare shares sinking today? appeared first on The Motley Fool Australia.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;

To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.

An active and funded account with a positive trading balance is required to continue to have access to the tools;

Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;

Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!